Related Experiment Video
Updated: Jun 9, 2025
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
Deciphering the regulatory mechanisms and biological implications of ARID1A missense mutations in cancer
Fang Liu1, Jun Ying2, Kai Yang3
1Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Systems Medicine for Cancer, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Department of Laboratory Medicine, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201803, China.
Abstract:
ARID1A is a key component of the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex and functions as a critical tumor suppressor in various cancers. In this study, we find that tumor cells with hotspot missense mutations in ARID1A (AT-rich interactive domain-containing protein 1A) exhibit a malignant phenotype. Mechanistically, these mutations facilitate the translocation of ARID1A mutant proteins to the cytoplasm by the nucleocytoplasmic shuttler XPO1 (exportin 1). Subsequently, the E3 ubiquitin ligase STUB1 ubiquitinates the ARID1A mutant protein, marking it for degradation. Knocking down STUB1 or inhibiting XPO1 stabilizes the ARID1A mutant protein, retaining it in the nucleus, which restores the assembly of the cBAF complex, the chromatin remodeling function, and the normal expression of genes related to the MAPK and anti-apoptotic pathways, thereby decreasing the tumor burden. Our research shows that nuclear-localized mutated ARID1A proteins retain tumor-suppressive function. We identify promising strategies to treat cancers harboring missense mutations in the BAF complex.
Insights
Mutated ARID1A proteins can suppress tumors when returned to the nucleus. Inhibiting XPO1 or STUB1 restores nuclear ARID1A, offering new cancer treatment strategies for SWI/SNF complex mutations.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- ARID1A is a crucial tumor suppressor within the SWI/SNF chromatin remodeling complex.
- Mutations in ARID1A are linked to a malignant phenotype in various cancers.
Purpose of the Study:
- To investigate the mechanism by which ARID1A mutations drive cancer progression.
- To identify therapeutic strategies targeting cancers with ARID1A mutations.
Main Methods:
- Analysis of ARID1A mutant protein localization and stability.
- Investigating the roles of XPO1 and STUB1 in ARID1A degradation.
- Assessing the impact of restoring nuclear ARID1A on cellular function and tumor burden.
Main Results:
- Missense mutations cause ARID1A to translocate to the cytoplasm via XPO1, leading to STUB1-mediated degradation.
- Inhibiting XPO1 or knocking down STUB1 stabilizes nuclear ARID1A.
- Restoring nuclear ARID1A reassembles the cBAF complex, normalizes gene expression, and reduces tumor burden.
Conclusions:
- Nuclear-localized ARID1A mutants retain tumor-suppressive activity.
- Targeting XPO1 or STUB1 represents a promising therapeutic approach for ARID1A-mutated cancers.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:23Abnormal Proliferation
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:31Regulation of the Unfolded Protein Response
02:38The Ras Gene
Ras is a...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...